Introduction
A national immunisation programme against pertussis was introduced in Sweden, as in many other countries, in the mid-1950s. After years of the incidence of the disease decreasing epidemics of pertussis started to occur in the 1970s. This resurgence was associated with a decreased efficacy of the vaccine and together with a growing concern about the safety of the vaccine led to the decision in 1979 to stop the routine use and production of pertussis vaccine. A plain whole cell vaccine (Pertussis Vaccine Wellcome; Weilcome) was imported from the United Kingdom in 1981 for limited use in children with cystic fibrosis and other conditions of high risk. '2 The possibility that a further increase in the incidence of the disease would necessitate reintroducing general vaccination prompted further studies of Wellcome's product. Our study was started in 1982 to collect information on the antibody response and adverse reactions to the vaccine and the protective efficacy of the vaccine. The data on side effects and serological efficacy by the neutralisation test have been presented elsewhere.34 This report investigates the efficacy of the vaccine in the clinical trial.
Subjects and methods
From mid-1982 to mid-1983 2 month old infants enrolled at 51 preventive care child health centres in Stockholm who had no known contraindications to pertussis vaccination5 were identified to participate in a non-blinded trial. Consent to participate was obtained from all the parents. Infants born on days with an even number were inoculated subcutaneously with three 0 5 ml doses of vaccine given one month apart, starting from the age of 2 months (mean 2-3 (SD 0-5) months, range 1-2-7-3 months). Children of the same age born on days with an odd number received no pertussis vaccine. Nurses at the child health centres were instructed to ask parents during the normal regular visits (every 2-4 months) whether the infants in the study had had pertussis and to note any symptoms on a special form kept in the medical records at the centres. Paediatricians at the primary care facilities affiliated with these centres were asked to examine all participants with suspected pertussis and report their findings on a special form.
In February 1985 the report forms of partcipating infants were collected to ascertain the number of cases of pertussis that had occurred in the study population between the ages of 6 and 23 months. In addition, the regular medical records kept at the child health centres were reviewed and the files of laboratory reports to the National Bacteriological Laboratory in Stockholm searched for positive results on culture for children in the study. This laboratory is a governmental agency that receives reports on all positive cultures for pertussis from laboratories throughout Sweden. All samples taken for serological tests from children in the study were identified by a systematic search in the files of the only two laboratories that perform routine serological tests for pertussis. The samples were retested by methods indicated below.
Cases of pertussis were considered to be confirmed by the laboratory if they yielded positive results on culture for Bordetella pertussis or positive serological findings, which were defined as a significant rise in titres in an enzyme linked immunosorbent assay (ELISA) to detect antibodies against filamentous haemagglutinin and pertussis toxin6 7or in a neutralisation test in Chinese hamster ovary cells to detect antibodies against pertussis toxin,89 or both. B pertussis was cultured in routine laboratories and therefore the serotypes were unknown. The serological assays used were found to have a diagnostic sensitivity in terms of raised titres of 100% in 90 cases of pertussis that were confirmed by the results of culture (unpublished data).
Cases of pertussis that were not confirmed by laboratory results were included if infants had had typical symptoms such as coughing for more than four weeks, whoops, or coughing with vomiting. In addition, whooping cough had to have been diagnosed by a doctor or have been linked epidemiologically-that is, the infant had been in contact with another patient with whooping cough-or both. These data were supplemented by contacting the parents and the doctors who had diagnosed the disease.
Statistical analyses of attack rates were performed with corrected X2 tests and comparison of two independent proportions. Confidence intervals on estimates of the vaccine's efficacy were calculated as described by Orenstein et al. ' 
Results
Immunisation with three doses of pertussis vaccine from 2 months of age was completed in 525 children. Immunisation was started in 562 infants, but seventeen infants who received only two doses of vaccine and twenty who received only one dose were excluded from the analysis. Altogether 615 children were enrolled as controls.
A total of 55 cases of pertussis occurred among 1140 study participants between the ages of 6 and 23 months ( (8/525 ) and significantly lower than that of 5-2% (32/615) in unvaccinated children (p<0 01). The estimated efficacy of the vaccine in the cases that were confirmed by laboratory results was thus 71% (95% confidence interval 37 to 86), which was similar to that of 72% (95% confidence interval 27 to 89) for cases confirmed by the results of culture alone.
Discussion
Few controlled trials of the efficacy ofwhole cell pertussis vaccine have been conducted since the trials by the British Medical Research Council over 30 years ago." 12 The situation in Sweden after 1979 provided a unique opportunity to repeat a clinical trial of the efficacy of whole cell vaccine several years after licensure and thereby obtain updated information on this type of pertussis vaccine. Since licensure, numerous reports have estimated the efficacy of the vaccine retrospectively, most commonly from outbreaks of pertussis when attack rates in vaccinated and unvaccinated subjects have been compared. These estimates have, however, varied greatly and it has been difficult to establish the effectiveness of whole cell vaccine. 13 In our prospective controlled study we allocated subjects by date of birth to the vaccinated and unvaccinated groups and used multiple sources of information to establish cases of pertussis, and a high percentage of our cases were confirmed by laboratory results.
The design of the study should have ensured that the groups were comparable with regard to risk of exposure, and the multiple sources of information should have ensured that all cases of p,ertussis were properly established. The trial was, however, not blind and despite the many opportunities for a child to be reported to the study as having pertussis evidence exists that all cases of the disease may not have been reported in the unvaccinated group-for example, the percentage of vaccinated children for whom study forms were collected was slightly higher than that for unvaccinated children (74% v 67%, respectively), and review of records was also more complete for the vaccinated children (78% v 66%). In addition, doctors seemed to seek laboratory confirmation more often for children who were vaccinated; thus serjim samples were taken about as often for children who were vaccinated (33 out of 525) as for those who were not vaccinated (37 out of 615), even though the attack rate was higher in the unvaccinated children. This preference by doctors for laboratory confirmation among vaccinated children could explain the fall in the vaccine's estimated efficacy from 80% for all cases to 71% for cases with laboratory confirmation alone. A plausible explanation may be that pertussis is a less typical illness among vaccinated children, requiring more laboratory support to be diagnosed. If a bias were introduced by these differences in ascertainment of cases between the groups its direction would be towards artificially low estimates of the vaccine's efficacy.
Our overall estimate of the vaccine's efficacy of 80% is similar to that found in the trials over 30 years ago. Several problems in interpreting or generalising these results to other populations should be noted. The use of plain rather than adsorbed whole cell vaccine and the lack of a booster injection may explain why our estimate is lower than that observed in some other studies. 13 Adsorbed pertussis vaccines are currently more commonly used and have been shown in several studies to give a better agglutinin response. 14 A difference in protective efficacy between adsorbed and plain vaccines has not been proved, but studies comparing the two types of vaccine from the same manufacturer have not been large enough to show small differences in efficacy. 5 Many studies of the agglutinin response after vaccination against pertussis have shown a higher rate ofresponse and higher titres after booster injections than after primary immunisation. 15 The antibody response to pertussis toxin (antitoxin) may better reflect long term immunity to disease.9 An antitoxin response with this plain whole cell vaccine was elicited after a primary series in about 60% of the infants in two studies4 16 and in 98% of a subset of children in our trial, who received a booster injection (unpublished observations). Although the protective efficacy during our study did not decrease significantly, we saw a slight trend in that direction, and the lack of significance may be due to the small numbers.
In conclusion, we obtained an overall estimate of 80% for the efficacy of a plain whole cell pertussis vaccine given in a primary series of three doses to 2 month old infants. As we found some evidence for selective ascertainment of cases the value obtained may represent an underestimate of the true efficacy of this vaccine and may be lower than that achievable in countries that use a regimen of three doses and one or more booster injections ofadsorbed pertussis vaccine. Case reports Case I-A 41/2 year old boy presented with a three hour history of vomiting, abdominal pain, and drowsiness. He had previously been well, and his medical history was unremarkable. On examination he was not feverish but was tachycardic, tachypnoeic, and peripherally shut down. His abdomen was soft and not obviously tender or distended. Before much investigation had been carried out, however, his condition deteriorated further, and in spite of vigorous attempts at resuscitation he died. Postmortem examination showed that virtually all of the small intestine was ischaemic, with twisting of the root of the mesentery. The cause of death was recorded as volvulus of the small bowel.
Case 2-The younger brother of the patient in case 1 was referred to this hospital at the age of 4 with a history of two episodes of sudden abdominal pain associated with profuse vomiting. These episodes settled quickly without treatment, and no haematological or radiological abnormalities were found when he was examined, although his symptoms had subsided by this time. Because his parents were naturally worried that the symptoms were caused by small bowel volvulus, as in their first son, a laparotomy was performed. This was decided on because even if other investigations-for example, barium enema or barium meal and follow through-had yielded normal results the parents would not have been reassured until a laparotomy had been performed. Surprisingly, at laparotomy the bowel was found to be malrotated and the small bowel to be suspended on a long, narrow based mesentery, which showed signs of previous episodes of volvulus. The malrotation was treated, and he made a good recovery, experiencing no further problems.
Comment
Malrotation of the small intestine is caused by disordered movement of the intestine around the superior mesenteric artery during embryological development.3 Two main abnormalities that produce clinical syndromes may occur. In the first narrowing of the base of the mesentery occurs, which may allow the midgut to twist and cause a volvulus. This may occur acutely, causing complete obstruction, or intermittently, producing bouts of obstruction that resolve spontaneously. In 
Patients, methods, and results
Nine men and nine women (mean age 23-7 years) were studied. All had a five year history of seasonal rhinitis and gave positive results to skin prick tests with mixed grass pollen (2 5% weight/volume) and negative results to skin prick tests with house dust (150% weight/volume) and house dust mite (1-2% weight/volume.) A biopsy sample was taken from the inferior turbinate of each patient during the first week of March 1986 before the grass pollen season started. Patients were randomised (with a random number table) in May 1986 to receive double blind treatment with beclomethasone dipropionate (Allen and Hanburys Ltd, Greenford, UK) or placebo 100 [sg twice a day to each nostril from identical
